Bausch Health Companies Inc SEC Filings

FAT Brands Inc. filed a Form 8-K on 30 Jul 2025 to furnish—not file—its second-quarter 2025 earnings materials. Under Item 2.02, the company states that a press release (Exhibit 99.1) summarizing results for the 13- and 26-week periods ended 29 Jun 2025 was issued the same day. Item 7.01 notes that a supplemental slide deck (Exhibit 99.2) has been posted to the investor website for use during the earnings call.

Management hosted a conference call on 30 Jul 2025; a telephone replay will be available until 20 Aug 2025 (passcode 13754156) and a webcast replay remains on the company’s site. Because the 8-K contains no actual financial figures or guidance, investors must consult the attached exhibits to assess revenue, EBITDA, margins, or outlook. The furnished status means the data is not subject to Section 18 liability unless later incorporated by reference.

Form 4 filed for Bausch Health Companies Inc. (BHC) reports that director Michael Goettler received 30,149 restricted share units (RSUs) on 25 Jul 2025. The transaction is coded “A,” indicating an equity award rather than an open-market purchase, and carries a stated acquisition price of $0. Each RSU entitles the holder to one common share and will vest immediately before BHC’s 2026 annual shareholders’ meeting. After the grant, Goettler’s direct beneficial ownership totals 30,149 common shares. No sales, options, or other derivative activities were disclosed.

This filing represents customary director compensation and contains no operational, earnings, or guidance information for BHC. The grant marginally increases insider equity alignment but is unlikely to have a material impact on the company’s financial position or market outlook.

Huntington Ingalls Industries (HII) filed an 8-K reporting a governance change under Item 5.02. Effective 29-Jul-2025, the Board elected Nick L. Stanage, former Chairman & CEO of Hexcel Corporation, as a director and increased the Board size from 12 to 13 members.

Stanage is assigned to the Audit Committee and the Governance & Policy Committee. He will receive an annual cash retainer of $120 k plus $25 k (Audit) and $20 k (Governance) committee fees, and an annual equity grant of $165 k in deferred stock units, all prorated for 2025.

No financial results, strategic transactions, or other material events were disclosed.

Bausch Health (BHC) will acquire DURECT Corp. (DRRX). Its subsidiary will tender for all shares at $1.75 cash plus one CVR per share. The CVR provides up to $350 M in milestone payments. Up-front cash of about $63 M equals a 191 % premium to 30-day VWAP and 217 % to last close.

The deal adds larsucosterol, an epigenetic modulator with FDA Breakthrough Therapy status for alcoholic hepatitis that showed positive Phase 2 data. BHC plans a randomized Phase 3 trial; the drug complements its rifaximin SSD program in hepatology.

Closing requires a majority tender and customary conditions; targeted for Q3 2025. Untendered shares will be acquired via a follow-on merger at identical terms. Offer documents will be filed on Schedule TO and 14D-9.

Duke Energy Corporation, through its wholly owned subsidiary Piedmont Natural Gas Company, signed an Asset Purchase Agreement on 27-Jul-2025 to divest Piedmont’s Tennessee natural-gas local distribution company business to Spire Inc. for $2.48 billion cash, subject to working-capital, regulatory-asset and cap-ex adjustments.

Closing is contingent on (i) HSR antitrust clearance, (ii) approval by the Tennessee Public Utility Commission, (iii) absence of a Material Adverse Effect and (iv) usual accuracy & covenant bring-downs. No financing condition applies and management targets completion in Q1 2026. Either party may terminate if the deal is not closed by 27-Apr-2026 (extendable three months solely for outstanding regulatory approvals); Buyer owes a termination fee in specified circumstances.

Until closing, Piedmont must operate the business in the ordinary course and observe additional covenants. Duke furnished a press release (Ex. 99.1) and a transaction overview (Ex. 99.2) with this Form 8-K.

On 23 Jul 2025, ESSA Bancorp (ESSA) closed its merger with CNB Financial (CNB) under the 9 Jan 2025 agreement.

• Each ESSA share was converted into 0.8547 CNB shares; cash will be paid for fractional shares.
• ESSA restricted stock immediately vested and converted into merger consideration; performance-based RSUs vested at ≥ target and were settled in cash.
• ESSA Bank & Trust simultaneously merged into CNB Bank.

Corporate effects:

• ESSA common stock will be delisted from Nasdaq, and CNB will file Form 25 and Form 15 to end ESSA registration and periodic reporting.
• ESSA ceased to exist; CNB’s amended certificate of incorporation and bylaws remain governing documents.
• ESSA’s directors and executives resigned; former CEO Gary S. Olson and directors Robert C. Selig, Jr. and Daniel J. Henning join CNB/CNB Bank boards.

Exhibits include the full merger agreement (Ex 2.1) and a 24 Jul 2025 CNB press release (Ex 99.1) confirming completion.